Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006223 · ClinicalTrials.gov registry record · Phase 3
flt3L in Treating Patients With Acute Myeloid Leukemia
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00006223 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00006223, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs such as flt3L may stimulate a person's immune system and help kill cancer cells. It is not yet known if flt3L is effective in treating acute myeloid leukemia. PURPOSE: Randomized phase III trial to determine the effectiveness of flt3L in treating patients who have acute myeloid leukemia that is in remission.
Interventions
- BIOLOGICAL recombinant flt3 ligand
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006223
The ClinicalTrials.gov registry entry for NCT00006223 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant flt3 ligand is the first listed.
NCT00006223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006223 about?
NCT00006223 is a clinical study titled "flt3L in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs such as flt3L may stimulate a person's immune system and help kill cancer cells. It is not yet known if flt3L is effective in treating acute myeloid leukemia. PURPOSE: Randomized phase III trial to determine the effectiveness of flt3L in treating patients who have acute myeloid leu...
What is the current status of trial NCT00006223?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-07. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00006223?
The interventions under investigation include: recombinant flt3 ligand (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006223?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.